Ann: Quarterly Activities Report Appendix 4C, page-48

Hilarious to watch some people lose their heads over minor delays with the BBI project due to the IPO - which everyone is aware of because it was well publicised and discussed in this forums too.

The fundamental questions I asked myself were:

Do our stakeholders remain engaged and interested in our product? - Yes. No one has walked away.

Are we making progress with in our projects with our partners? Yes. "Our PoC 1 project was successfully completed. A decision has been made to expand Mix&Go testing to include sensor surface allowing a more holistic approach to be made"

Does M&G remain a proven product? - Yes. It continues to deliver on its promises and more. This is not just GC's view, but the views shared by our partners who are using M&G.

Are the opportunities for M&G expanding or narrowing? Expanding. "Mix&Go is being evaluated for an increasing variety of purposes ranging from biosensors and veterinary uses to blood screening."

Does the company continue to remain well funded? Yes - $7 million in the bank. We are also getting paid for some of our work as well which will further offset costs. Although I don't think it is needed, from memory, Bouris' 5 million 12 cent options also come into play in December this year.

If you can't fathom a delay of just a couple of months with just one partner who had to go through an abortive IPO process that was well publicised months ago... then please sell out, and rethink whether investing is for you.

Others invested in the companies fundamentals would love to scoop them up at a cheaper price.

Today's price doesn't matter unless you're looking to buy or sell in the short term. For people actually interested in the long term, what matters is what the final outcome of our projects with our partners, BBI and POC1. That will either put a rocket under the SP or rain on it. The info to date suggests that it's more likely to be a rocket than rain as M&G has continues to prove is value and more.